Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) EBIT Margin (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported EBIT Margin over the past 12 years, most recently at 92991.67% for Q4 2025.

  • Quarterly results put EBIT Margin at 92991.67% for Q4 2025, up 2849722.0% from a year ago — trailing twelve months through Dec 2025 was 512.91% (up 9850563.0% YoY), and the annual figure for FY2025 was 512.91%, up 9850530.0%.
  • EBIT Margin for Q4 2025 was 92991.67% at Viridian Therapeutics, Inc.\DE, down from 56.7% in the prior quarter.
  • Over the last five years, EBIT Margin for VRDN hit a ceiling of 56.7% in Q3 2025 and a floor of 142356.0% in Q2 2025.
  • Median EBIT Margin over the past 5 years was 72548.24% (2023), compared with a mean of 59249.63%.
  • Biggest five-year swings in EBIT Margin: tumbled -7077795bps in 2023 and later soared 9701307bps in 2025.
  • Viridian Therapeutics, Inc.\DE's EBIT Margin stood at 13589.25% in 2021, then plummeted by -244bps to 46729.52% in 2022, then plummeted by -112bps to 99275.0% in 2023, then dropped by -22bps to 121488.89% in 2024, then rose by 23bps to 92991.67% in 2025.
  • The last three reported values for EBIT Margin were 92991.67% (Q4 2025), 56.7% (Q3 2025), and 142356.0% (Q2 2025) per Business Quant data.